Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
Breast cancer care needs sharper radiation decisions. PreludeDx’s AidaBREAST now faces the harder test of validation, adoption and access.
Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions
See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.
Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.
What QT Imaging’s latest FDA clearance reveals about the future of radiation-free breast imaging
QT Imaging wins FDA clearance for an upgraded Breast Acoustic CT scanner. Discover what this means for radiation-free breast imaging.
Exact Sciences unveils key Oncodetect results in TNBC: Is this a reimbursement turning point?
Exact Sciences Corporation has presented first-time clinical results for its Oncodetect molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC), showcasing a strong correlation between circulating tumor DNA (ctDNA) detection and recurrence risk following neoadjuvant therapy and surgery. The results, drawn from a 147-patient cohort in the NSABP B-59 substudy, were unveiled at […]